Clinical Trial Update: Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine [NA]

View source ↗

Summary

This completed trial evaluated the immunogenicity of JE-CV as a booster dose after primary vaccination with SA14-14-2 for Japanese encephalitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• JE-CV (ChimeriVax-JE) (Japanese encephalitis vaccine - chimeric live attenuated JE-CV)
• SA14-14-2 vaccine

Snippet

Sponsor: Chulalongkorn University | Conditions: Japanese Encephalitis | NA | Status: COMPLETED